Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma
- PMID: 15101997
- DOI: 10.1111/j.1478-3231.2004.00882.x
Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma
Abstract
Transforming growth factor-beta1 (TGF-beta1) has been implicated in tumor progression. The relationship of this cytokine as measured in plasma to anti-tumor immunity and prognosis was investigated. This study consisted of 70 consecutive patients with unresectable hepatocellular carcinoma (HCC) (median age, 65 years). Forty-four healthy age-matched subjects and 32 patients with cirrhosis but no carcinoma served as controls. Patients with HCC were divided into those with plasma TGF-beta1 concentrations above (group A, n=21) or below (group B, n=49) 10 ng/ml (the mean concentration+2SD in the concentrations of the controls with cirrhosis was 8.7 ng/ml). Age, gender, Child-Pugh grade, and tumor stage distributions were similar in groups A and B. Considering all tumor stages together and individually, group A had a significantly shorter survival (median for all stages, 2 months) than group B (median for all stages, 10 months; P<0.01, generalized Wilcoxon's test). Groups A and B had significantly shorter survival than controls with cirrhosis (P<0.001 for each). Lymphokine-activated killer (LAK) activity in group A was significantly lower than that in group B (P<0.001). Natural killer (NK) activity in group A was also significantly lower than that in group B (P<0.05). Plasma TGF-beta1 concentration was a significant predictor of survival by Cox's proportional-hazards regression analysis (multivariate analysis, P<0.01). LAK and NK activities were also weak but significant predictors (P<0.05 and <0.05, respectively). These data suggest that plasma TGF-beta1 concentration is a predictor of outcome of patients with unresectable HCC. Circulating TGF-beta1 supposedly contributes to the suppression of anti-tumor immunity in the advanced disease.
Similar articles
-
Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma.Cytokine. 2000 Jun;12(6):811-4. doi: 10.1006/cyto.1999.0650. Cytokine. 2000. PMID: 10843770
-
Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma.Hepatobiliary Pancreat Dis Int. 2008 Jun;7(3):288-95. Hepatobiliary Pancreat Dis Int. 2008. PMID: 18522884
-
Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer.Clin Cancer Res. 2001 May;7(5):1258-62. Clin Cancer Res. 2001. PMID: 11350892
-
The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.Clin Ter. 2004 May;155(5):187-99. Clin Ter. 2004. PMID: 15344567 Review.
-
Locoregional immunochemotherapy in hepatocellular carcinoma.Hepatogastroenterology. 2002 Jul-Aug;49(46):1109-12. Hepatogastroenterology. 2002. PMID: 12143214 Review.
Cited by
-
Immunomodulatory effects of transforming growth factor-β in the liver.Hepatobiliary Surg Nutr. 2014 Dec;3(6):386-406. doi: 10.3978/j.issn.2304-3881.2014.11.06. Hepatobiliary Surg Nutr. 2014. PMID: 25568862 Free PMC article. Review.
-
Evaluation of circulating Transforming growth factor-beta1, Glypican-3 and Golgi protein-73 mRNAs expression as predictive markers for hepatocellular carcinoma in Egyptian patients.Mol Biol Rep. 2013 Dec;40(12):7069-75. doi: 10.1007/s11033-013-2829-3. Epub 2013 Nov 2. Mol Biol Rep. 2013. PMID: 24186850
-
Mechanistic basis and clinical relevance of the role of transforming growth factor-β in cancer.Cancer Biol Med. 2015 Dec;12(4):385-93. doi: 10.7497/j.issn.2095-3941.2015.0015. Cancer Biol Med. 2015. PMID: 26779375 Free PMC article. Review.
-
Advanced molecular surveillance of hepatitis C virus.Viruses. 2015 Mar 13;7(3):1153-88. doi: 10.3390/v7031153. Viruses. 2015. PMID: 25781918 Free PMC article. Review.
-
Natural killer cell is a major producer of interferon gamma that is critical for the IL-12-induced anti-tumor effect in mice.Cancer Immunol Immunother. 2010 Mar;59(3):453-63. doi: 10.1007/s00262-009-0764-x. Epub 2009 Sep 16. Cancer Immunol Immunother. 2010. PMID: 19756594 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous